GLP-1 Cancer Link Debunked? New Study Shocks!

Recent research indicates that popular GLP-1 medications, including Ozempic and Zepbound, may not offer the anticipated benefits in reducing the risk of obesity-related cancers. A large-scale review of 48 randomized controlled trials, encompassing nearly 95,000 participants, found that these drugs likely have minimal to no impact on the development of 13 specific obesity-related cancers.

The study, which analyzed data from patients with Type 2 diabetes, overweight, or obesity, observed that despite the weight loss associated with GLP-1 drugs—a factor known to influence cancer risk—the medications themselves did not demonstrate a significant reduction in cancer incidence. Researchers concluded with moderate certainty that GLP-1s had little effect on breast, kidney, thyroid, and pancreatic cancers, with varying levels of certainty for others.

While the findings suggest GLP-1 drugs are unlikely to increase cancer risk, experts emphasize the need for longer-term studies. Current research limitations include trials not specifically designed to assess cancer outcomes and relatively short follow-up periods. Nevertheless, the study provides some reassurance regarding the safety of these drugs for their primary uses in managing obesity and Type 2 diabetes.